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ABSTRACT
Purpose: To determine whether digital spatial intensity patterns can be developed to effect precise in vitro correction of
myopic, hyperopic, and astigmatic refractive errors in a silicone light-adjustable lens (LAL). Also, to determine whether
a new spatial intensity pattern for “lock-in” is effective in vitro.  
Methods: A digital interferometer/irradiation system was developed to irradiate LALs and measure the power change
following irradiation. Light-adjustable lenses were mounted into a wet cell maintained at 35.0 ± 0.5°C (simulated ocular
temperature) and allowed to equilibrate for a minimum of 2 hours. Ultraviolet light was then applied with spatial light
intensity patterns to correct hyperopia, myopia, and astigmatism. Light-adjustable lenses were also treated to effect lock-
in with a separate spatial light intensity pattern. Treated lenses were characterized for power change and optical quality.
In the case of lock-in, exhaustive chemical extraction was also performed to determine the percentage of remaining
macromer.
Results: Appropriate digital irradiation spatial intensity patterns were created to develop nomograms for in vitro
correction of myopia, hyperopia, and astigmatism in approximate 0.25 D steps.  Power changes were reproducible and
did not alter optical quality of the LALs.  Further, lock-in dosing of the LALs did not alter optical quality or significantly
change LAL power.
Conclusions: In vitro nomograms have been developed for a silicone LAL that permit precise correction of myopia,
hyperopia, and astigmatism. Furthermore, a spatial light intensity pattern has been devised that effects lock-in without
significantly altering LAL power or optical quality. 
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INTRODUCTION
With current intraocular lens (IOL) designs and biometry,
more than 95% of cataract surgery patients achieve best-
corrected visual acuity of 20/40 or better.1-3 Residual
postoperative refractive error in these patients often
creates a gap between uncorrected visual acuity and best-
corrected visual acuity, leaving approximately one third of
patients in need of spectacles for optimized distance
vision. The discrepancy between postoperative corrected
and uncorrected distance vision is often due to inaccurate
IOL power determination and preexisting astigmatism.4-12
Further difficulties in appropriate IOL power
determination are encountered in patients who have
undergone previous corneal refractive procedures.13-16 A
means to postoperatively correct residual spherical and
astigmatic refractive errors after cataract surgery would
allow a greater number of IOL patients to achieve the
desired refractive outcome.
Previous investigators have recognized the need for
an IOL with the capacity of postoperative power
adjustment.17-22 While potentially enabling adjustment of
IOL power postoperatively, these lens designs require
invasive adjustment procedures and/or do not allow
correction of astigmatism and higher-order optical
aberrations. 
Recently, we reported on a silicone light-adjustable
lens (LAL) that is adjusted using safe levels of ultraviolet
light.23 The LAL formulation consists of four basic
components: a silicone matrix polymer, macromer,
photoinitiator, and ultraviolet light absorber. The LAL
material is a clear and flexible elastomer capable of
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folding during implantation. After implantation, the lens
power may be increased or decreased noninvasively by
the application of the appropriate spatially resolved
irradiation profile. Upon irradiation with 365-nm light,
the macromer molecules in the irradiated region are
photopolymerized to form an interpenetrating network.
This produces a concentration gradient between the
irradiated and unirradiated regions of the lens. Macromers
from the unirradiated portion of the lens diffuse along this
concentration gradient into the photopolymerized portion
of the lens to reestablish thermodynamic equilibrium.
Macromer diffusion produces a swelling in the irradiated
region that effects a change in the lens curvature with a
concomitant power change. When the central portion of
the lens is irradiated preferentially and the periphery left
nonirradiated, macromer diffuses into the center of the
lens, causing an increase in the lens power and a hyperopic
shift (Figure 1). By irradiating preferentially the peripheral
portion of the lens, macromer migrates outward, causing a
decrease in lens power, producing a myopic correction.
The refractive index of the macromer is designed to match
the silicone matrix for optimal optical compatibility;
therefore, the power change of the LAL upon irradiation
is induced primarily by the shape (radius of curvature)
change.
Once the appropriate power adjustment is achieved,
approximately 12 to 18 hours after irradiation, the entire
lens is irradiated to “lock in” and stabilize lens power by
polymerizing the remaining reactive macromer. By
irradiating the entire lens with the appropriate profile,
there is no macromer diffusion and thus no further
change in lens power.
In our previous report, we addressed issues of
biocompatibility and efficacy of the LAL in a rabbit model.23
Preliminary efforts at developing a nomogram for myopic
adjustments of LAL power were also presented. Herein we
determine whether digital spatial intensity patterns can be
developed to effect precise in vitro correction of myopic,
hyperopic, and astigmatic refractive errors.  We also test a
new spatial intensity pattern for lock-in.
METHODS
Work was performed at Calhoun Vision, Inc, Pasadena,
California. A digital interferometer/irradiation system was
developed in the laboratory to irradiate the LALs and
measure the power change following irradiation. There
are two main components of this optical instrument
(Figure 2). The first is the irradiation system, which is
composed of a mercury (Hg) arc lamp filtered to 365 nm
(±5 nm full width half maximum), a critical
illumination/projection system, and a digital mirror
device. This device is a pixelated, micromechanical spatial
light modulator formed monolithically on a silicon
substrate. Typical digital mirror device chips have
dimensions of 15.1 mm × 12.7 mm. The individual
micromirrors are 13 to 17 µm on an edge and are covered
with an aluminum coating. The micromirrors are arranged
in an xy array, and the chips contain row drivers, column
drivers, and timing circuitry. The addressing circuitry
under each mirrored pixel is a memory cell that drives two
electrodes under the mirror with complementary
voltages. Depending on the state of the memory cell (a “1”
or “0”), each mirror is electrostatically attracted by a
combination of the bias and address voltages to one of the
other address electrodes. Physically the mirror can rotate
±10 degrees. A “1” in the memory causes the mirror to
rotate +10 degrees, whereas a “0” in the memory causes
the mirror to rotate –10 degrees. A mirror rotated to +10
degrees reflects incoming light into the projection lens
and onto the LAL. When the mirror is rotated –10
degrees, the reflected light misses the projection lens and
FIGURE 1
Correction of hyperopia with the light-adjustable lens (LAL).  The clear
material represents the matrix of the lens. Yellow strands represent
macromer. The initial implant is viewed from the side and from the front
(A). The central zone of the lens is treated with UV light (365 nm) to
activate the photoinitiator, causing the macromer in the central zone to
polymerize (blue strands) (B). At this point the shape of the lens has not
significantly changed. Free macromer from the unirradiated portion of
the lens diffuses down the concentration gradient between highly
concentrated macromer in the unirradiated zone and depleted macromer
in the irradiated zone, causing the central zone to swell (C). The
increased curvature of the central zone decreases the focal length,
correcting for hyperopia. Once the desired adjustment of the lens has
been achieved, the adjusted lens is “locked” by irradiating the entire lens,
causing all of the free macromer to polymerize without further altering
the shape of the lens (D).
FIGURE 2
Optical schematic of the interferometer/irradiation system.
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LAL. Thus, the great utility and advantage of the digital
mirror device in its relation to the LAL is the ability to
easily define a particular spatial intensity profile, program
this into the device, and then irradiate the LAL. Because
of the digital nature, the digital mirror device technology
offers greater resolution of the spatial light profile,
enabling the delivery of more precise, complex patterns to
provide greater range and control to the LAL corrections.
The optical analysis portion of this instrument utilizes
a phase-shifting Fizeau interferometer (Wyko model 400)
operating in double-pass configuration fitted with a 4-inch
transmission sphere. In practice, a set of LALs is first
mounted into the wet cell maintained at 35.0 ± 0.5°C
(simulated ocular temperature) and allowed to equilibrate
for a minimum of 2 hours. The wet cell is adjusted along
the optical axis of the interferometer until the power in
the wavefront across the full test aperture is minimized 
(≤ 0.010 waves). A measurement of the wavefront in the
exit pupil of the LAL and its position along the radius slide
are recorded, followed by irradiation of the lens. The total
time for macromer diffusion is between 12 and 18 hours
and depends upon the applied intensity and time. At 24
hours after irradiation, the LALs are returned to their
original position on the radius slide followed by
measurement of the LAL’s adjusted wavefront. Analysis of
the postirradiated wavefront, along with subtraction of the
preirradiated and postirradiated wavefronts, gives direct
information regarding the magnitude of the induced
power change, the size of the affected area, and any
changes in the other aberrations induced by the
irradiation procedure (eg, spherical aberration, coma,
astigmatism). Knowledge of the spatial intensity profile
applied to the LAL, coupled with the analysis of the
altered wavefront, allows guidance in the modification of
the pattern to produce the desired changes.
The LALs before and after irradiation were
characterized for power change and optical properties by
measuring magnification (line pair separation method),
resolution (US Air Force target method), and modulation
transfer function.24 The spectral transmittance of the
preirradiated and postirradiated LAL material was also
assessed by ultraviolet-visible spectrophotometry.
To assess lock-in efficacy, exhaustive chemical analysis
of extractables was used to determine the percentage of
remaining macromer. 
RESULTS
Figure 3 shows spatial intensity patterns for correction of
hyperopia (a) and myopia (b) and a “flat-top” spatial
intensity pattern used for lock-in irradiation (c).
A representative 2 D myopic adjustment is shown in
Figure 4a, where the periphery of the LAL was irradiated,
causing the diffusion of macromers from the central
portion of the lens out to the lens periphery. The
interference fringes are depicted 24 hours after
irradiation at the preirradiation focus position. The most
striking feature of this figure is the addition of
approximately 12 fringes (in double pass) of defocus
(optical path difference) added to the lens, which
corresponds to –2.0 D of myopic correction.
Optical characterization of the LALs before and after
irradiation by measuring resolution (US Air Force target
method), modulation transfer function,24 and spectral
transmittance shows no significant change following
irradiation (Figure 4b, c, d).  
Results from optical testing to generate nomograms
for myopia and hyperopia are shown in Figure 5. Dose-
response curves are generated with gradations of
approximately 0.25 D from +0.75 D to +2.50 D for
hyperopia and –0.5 D to –2.75 D for myopia. Adjustments
are obtained with a precision of ≤ 0.25 D.
The flat-top lock-in spatial intensity patterns achieved
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FIGURE 3
Digital (left column) and graphic (right column) representations of
spatial intensity profiles for (a) hyperopic adjustment, (b) myopic
adjustment, and (c) lock-in treatment (“flat top” profile).
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successful lock-in of the LALs. This was confirmed by
exhaustive chemical extraction of explanted LALs from
the in vivo study in a rabbit model, which showed less than
1% remaining macromer. Results of photolocking 48
LALs demonstrate a change in lens power of less than
0.25 D (–0.08 ± 0.19) without altering lens optical quality
as determined by resolution efficiency (≥4-3) and
modulation transfer function measurement (0.43 ± 0.04).
FIGURE 4
Optical testing of the light-adjustable lens (LAL) upon irradiation. (a) Fizeau interference fringes of an LAL (base power +20 D) immersed in water at
35ºC before irradiation at best focus (double pass) and 24 hours after irradiation showing the addition of about 12 fringes (-2 D) to the preirradiated
lens, (b) resolution efficiency of an LAL before and after irradiation through a standard 1951 USAF target, (c) modulation transfer function curve before
and after irradiation, and (d) light transmittance curve before and after irradiation.
FIGURE 5
Hyperopic (a) and myopic (b) nomograms demonstrating reproducible
power adjustments with a precision of ±0.25 D.  Each point on the
nomogram consists of a minimum of 16 light-adjustable lenses per dose. 
FIGURE 6
Digital light delivery device, developed in collaboration with Zeiss-
Meditech.
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An astigmatic nomogram was generated using the
Zeiss digital light delivery device with an embedded
digital mirror device23 (Figure 6). The digital pattern
projected onto the LAL is shown in Figure 7a.
Representative three-dimensional wavefronts of two
irradiated LALs are shown in Figure 7b. The table in
Figure 7 shows dose-response data demonstrating
inducement of astigmatic power changes with
approximate 0.25 D steps between 1.0 and 2.0 D. 
DISCUSSION
We demonstrate that appropriate digital irradiation spatial
intensity patterns could be devised to create nomograms
for in vitro correction of myopia, hyperopia, and
astigmatism in the LAL. Using the appropriate spatial
intensity profile, nomograms with approximate 0.25 D
steps were developed. Power changes were reproducible
and did not alter optical quality of the LALs. Further, we
demonstrate that lock-in dosing of the LALs did not alter
optical quality nor significantly change LAL power. While
our previously reported study of the LAL showed a good
correlation between in vitro and in vivo adjustments in a
rabbit model, translating the current work into
nomograms for clinical use remains untested.
The human cornea has significant and important
differences from the rabbit that may limit the use of
nomograms presented above.25,26 The rabbit cornea is
about two thirds as thick as the human cornea and lacks
Bowman’s layer. Because the differences may affect light
transmission as well as scattering, use of the spatial light
intensity patterns and dosing may need to be altered as
the LAL is used clinically.27,28
With respect to corneal light transmission at 365 nm
in humans, there is considerable variation reported in the
literature. Values have ranged from 20% to 75%.29-31 This
large discrepancy may be explained by studies measuring
total (measurement of both the forward transmitted and
scattered light) versus direct (light transmitted through a
1-degree cone) transmission, a much smaller value. Also,
these measurements have been performed in vitro on eye
bank corneas and are not necessarily predictive of what
will be encountered in vivo.
Thus, although we have demonstrated the feasibility
of these novel IOL materials to be adjusted precisely to
correct hyperopia, myopia, and astigmatism, the
practicalities of using this system in patients remains to be
determined.
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DISCUSSION
DR ROGER F. STEINERT. Dr Schwartz and his colleagues
have described another key step in their development of a
novel technology. The ability to adjust the power and
possibly other optical characteristics of an IOL, such as
modifying multifocality and reducing high-order
aberrations, has captured the imagination of cataract and
refractive surgeons worldwide.  Rarely is pre-clinical
technology so well known and repeatedly discussed by
clinicians.  From the point of view of an outside observer
keenly intrigued by the potential for this device, the
process of this development has been characterized by a
rigorously designed and meticulously achieved series of
milestones. 
The current presentation is essentially a proof of
concept. After conceiving the chemical principle of
migrating macromolecules that could be polymerized
after IOL implantation by light, and then developing the
material in a form suitable for a lens, the inventors faced
the challenge of precise control of the delivery of the light
energy.  This required the development of the digital light
delivery system whose key component is the digital mirror
Light-Adjustable Lens: Development of In Vitro Nomograms
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device (DMD).
In an in-vitro laboratory setting, Dr. Schwartz and his
coworkers have now developed nomograms for control of
both hyperopic and myopic lens power changes presented
here.  The standard deviations are impressively tight, well
within clinically acceptable levels. Details about
methodology need to be expanded, however.  The text
indicates that “each point on the nomogram consists of a
minimum of 16 LALs/dose,” implying that the number of
lenses tested varied from group to group. Why?  Were
some results unexpected and the outliers discarded?  If so,
the standard deviation is artificially small. Similarly, we
would like much more detail about the lenses that were
photo locked and then tested for optical stability and
resolution.  Summary results are presented on 48 photo
locked LALs, again with apparently tight variability, but the
text is silent on the underlying data and method of statistical
analysis as well as the possibility of discarded data points.
Beyond these technical points, however, the authors
appropriately alert us to some of the future challenges.
One key question is the consistency of transmission of the
365-nanometer light by corneas of different patients.
Another major issue is safety.  While safety concerns are
beyond the scope of the current presentation, the
inventors will need to demonstrate the short- and long-
term safety of both the material and the ultraviolet light,
whose wavelength is toxic to the retina and the corneal
epithelium.  I have been assured that these concerns are
well known and being satisfactorily addressed by the
researchers.
Other issues will arise as this technology moves into
clinical testing.  Some of these issues are practical, such as
the need for patients to wear UV absorbing spectacles, at
least outdoors, in the days or weeks prior to photo locking,
and whether patients will comply with this.  
Many other issues are socioeconomic. The
technology of the digital light delivery system, the IOL
material itself, and the considerable extra surgeon and
technician time involved in the postoperative
interventions all add considerable expense.  As with some
other new IOL technologies, such as the accommodating
IOL, the restrictions on balance billing of cataract patients
have forced a business model in the U.S. where these
expensive technologies are marketed for refractive lens
exchange in patients without lens opacities.  How much
extra is such a patient willing to pay for optical perfection?
Notwithstanding these challenges, known and
unknown, Dr Schwartz and his coworkers are to be
congratulated both for their innovative technology and for
their methodical scientific development of its potential. 
DR DAVID L. GUYTON. To do the lock-in process, you have
to have a very widely dilated pupil to irradiate the whole
lens. There are many cataract patients whose pupils do
not dilate well. How critical do you view this problem and
do you have a solution for those cases where the pupil just
won’t dilate?
DR MICHAEL NORK. As a retinal specialist, I was hoping
that we had seen the end of silicone lenses since these
hydrophobic lenses present a difficulty when performing
retinal operations.  The lenses develop condensation,
making it difficult to see the retina once you perform an
air-fluid exchange. Although it is true that most people
with implants will never require a vitrectomy procedure,
on the other hand, most people that need vitrectomy
surgery are pseudophakic. Is there any way to coat the
lens or technologies to prevent condensation from
forming during air-fluid exchanges?
DR GEORGE L. SPAETH. From the point of view of quality
of life, what would be the benefit to the patient?
Resources are limited. Is the investment in this type of
technology justified in terms of other issues that need to
be solved?
DR DANIEL M. SCHWARTZ.  First, I would like to address
the issue of the number of lenses used for adjustment
nomograms and lock-in. As Dr Steinert notes, there were
variable numbers of lenses used to develop each point of
the nomograms. Our in-vitro lens adjustments/lock-ins
are performed in groups of eight lenses by one to three
scientists.  The nomogram data reported ranged from 16
to 48 lenses for each point generated by a minimum of
two different operators and represents the total number
of lenses tested under each condition.  All data collected
were reported with no data points rejected.  In spite of the
different operators, the data remained reproducible with
small standard deviations. 
Dr Steinert also raises the important potential
problem of variable corneal transmission of 365-
nanometer light used to irradiate the lenses. This is an
important issue because if there is variability from patient
to patient, it’s going to make this technology very difficult
to adopt by the practitioner. With the data to date, we
don’t know how much variability there’s going to be from
patient to patient. However, we have adjusted eight
consecutive patients since the manuscript was submitted.
Four were adjusted with an intended refractive change of
+1.5 diopters, 2 for +1.0 diopters, and 2 for -1.0 diopters.
After adjustment, all were within 0.25 diopters of the
intended refractive outcome.  One of the patients we
adjusted for +1.5 diopters was 50 years old and one was
85, and yet we achieved the same dioptric change. We are
using pachymetry measurements before and after surgery
to confirm that patients recover to their pre-op
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pachymetry levels, thus minimizing corneal edema as a
variable. Fortunately, the technology is somewhat tolerant
of these differences. We can get the same power changes
with about a 10 percent difference in corneal light
transmission. 
There are concerns about irradiation safety, and these
relate to potential damage to the cornea with
photokeratitis or damage to the retina from these UV light
sources. There is animal and human data on these
potential toxicities. The threshold for toxicity for
photokeratitis is approximately 70 joules per cm2 at 365
nm. We have not encountered any cases of photokeratitis
either in our rabbit studies for preclinical submission to
the FDA or in the patients that we have treated. 
We also are concerned about retinal toxicity, and the
retinal threshold in primates at this wavelength is
approximately 5.5 joules per cm2. Dr David Sliney is
widely published on the subject of the effects of UV
radiation on the eye and serves as member, advisor and
chairman of numerous committees and institutions which
are active in the establishment of safety standards for
protection against non-ionizing radiation (ANSI, ISO,
ICNIRP, ACGIH, IEC, WHO, NCRP).  He has advised
that we not exceed 2 joules per cm2 at the retina, and light
treatments are within that guideline.  
Dr Steinert raised some important issues about the
expense of the technology and the time requirement for
practitioners. I do not have detailed information about
these issues, but I can say the lens material itself is
surprisingly inexpensive. It costs just a few dollars more to
make this lens than conventional silicone lenses. The sales
price for the digital light delivery device is approximately
$80,000, which compares favorably with the excimer laser. 
As Dr Guyton notes, pupillary dilation is very
important. For typical adjustment and lock-in, spatial
intensity profiles are projected onto nearly the entire
6mm diameter of the IOL. We can customize the size of
the adjustment profile to accommodate smaller pupils;
however, the entire lens must be irradiated for lock-in. At
this time we are limiting the technology to patients who
dilate 7mm or more preoperatively. Undoubtedly there
will be some patients who dilate less after surgery. For
those patients, we could use a gonioscopic-type lens that
would direct light around the edges of the pupil to achieve
lock-in. We are also developing a second-generation lens
formulation that will not require lock-in. Pupillary dilation
would not be an issue with such a formulation since lock-
in would not be necessary.
Dr Nork raises an important issue about
condensations that can form on silicone IOLs during
vitrectomy surgery, especially when silicone oil is used.
The development of proliferative vitreoretinopathy (PVR)
requiring vitrectomy among those patients who develop
pseudophakic retinal detachments is probably on the
order of 5 to 7 percent. With PVR, equal success is
achieved using either gas or silicone oil, so silicone oil
would be avoided in patients with a silicone light
adjustable lens. For those patients in whom there is an
increased risk of retinal detachment recognized prior to
the cataract surgery, an adjustable silicone lens may not be
indicated. We are not restricted to silicone lenses and we
can adapt our technology to acrylic lenses, thereby
avoiding these condensation issues. We have developed a
prototype acrylic formulation that has been successfully
adjusted. 
Dr Spaeth asks how is this going to make our patients’
lives better, and is it really worth the cost?  I do believe
that there is a need for this technology since more patients
would like to be spectacle-free both at near and distance.
I have discussed a monofocal version of this lens, but we
can also make a customized multi-focal version of the lens.
Using the digital light delivery device, we can
emmetropize the eye and then create a multi-focal optic
in situ. Furthermore, if a patient will not tolerate multi-
focality, the multi-focal optic is potentially reversible.
Because of the ability to modify lens power multiple times
until it is locked in, we can also try a patient with
monovision and then reverse it if the patient wishes.  As
discussed above, the technology is going to be a fairly
insignificant increase in cost in terms of the IOL material.
Whether patients themselves will want to undergo
implantation with an adjustable IOL given the extra cost
related to financing the light delivery device and physician
time, only the market will provide the answer.  You still
have to perform a refraction, but the physician time for
adjustment and lock-in is minimal. Treatments are on the
order of 30 seconds to two minutes each for adjustment
and lock-in.
